Glucotrack (GCTK) Return on Capital Employed (2011 - 2025)
Glucotrack's (GCTK) quarterly Return on Capital Employed came in at 488.91% in Q4 2025, up 20249.0% YoY from N/an in Q4 2024, and down 17.44% on a QoQ basis from 416.32% in Q3 2025.
Glucotrack (GCTK) Return on Capital Employed (2011 - 2025) Analysis & Trends
Glucotrack (GCTK) has 14 years of Return on Capital Employed data on file, last reported at 488.91% in Q4 2025.
- Quarterly Return on Capital Employed rose 20249.0% year-over-year to 488.91% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 488.91% (up 20249.0% YoY) and the FY2025 annual result came in at 761.84%, down 41076.0% from the prior year.
- Return on Capital Employed declined to 488.91% in Q4 2025, from 416.32% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 524.66% in Q2 2024 to a low of 691.4% in Q4 2024.
- A 5-year average of 168.74% and a median of 135.8% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 63973 bps — and 2025, when it tumbled 75299 bps.
- Tracing GCTK's Return on Capital Employed over 5 years: stood at 66.6% in 2021, then plunged by 239 bps to 225.95% in 2022, then surged by 31 bps to 156.54% in 2023, then slumped by 342 bps to 691.4% in 2024, then grew by 29 bps to 488.91% in 2025.
- The last three Return on Capital Employed figures came in at 488.91% (Q4 2025), 416.32% (Q3 2025), and 225.59% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 18.58% |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 6.00% |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 28.11% |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 25.22% |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 5.57% |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 19.71% |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 19.76% |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 4.68% |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 3.28% |
| 10 | Glucotrack | 1.68 Mn | 553,542.53 | - | -952.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -488.91% |
| Sep 30, 2025 | -416.32% |
| Jun 30, 2025 | -225.59% |
| Mar 31, 2025 | -259.26% |
| Dec 31, 2024 | -691.40% |
| Sep 30, 2024 | 336.67% |
| Jun 30, 2024 | 524.66% |
| Mar 31, 2024 | -433.46% |
| Dec 31, 2023 | -156.54% |
| Sep 30, 2023 | -90.04% |
| Jun 30, 2023 | -115.06% |
| Mar 31, 2023 | -579.69% |
| Dec 31, 2022 | -225.95% |
| Sep 30, 2022 | -157.65% |
| Jun 30, 2022 | -114.96% |
| Mar 31, 2022 | -86.54% |
| Dec 31, 2021 | -66.60% |
| Sep 30, 2021 | -47.27% |
| Jun 30, 2021 | -44.00% |
| Mar 31, 2021 | -36.89% |